Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Mainly advanced and Metastatic Squamous cell esophageal carcinoma are diagnosed in the later stage of the disease, resulting from extensive surgical resection more or less associated with perioperative chemotherapy or neoadjuvant radiochemotherapy. Advanced and metastatic Squamous cell esophageal carcinoma becomes apparent with tumor growth, inability to swallow solids is followed by difficulty swallowing ground food and, finally, liquids. The advanced disease presents as polypoid intraluminal masses and loss of esophageal distensibility in the presence or absence of luminal narrowing. Progressive dysphagia is the most common complaint in most patients (90%) with greater than 50% luminal occlusion or where the luminal diameter is less than 13 mm. Squamous cell carcinoma represents 90% of EC in the world. It develops from squamous epithelium, from hyperplasia to dysplasia to cancer. At the molecular level, it is linked to particular TP53, NOTCH, and MTOR gene deregulation. Early-stage esophageal cancers are asymptomatic or may present with mild nonspecific symptoms such as heartburn, atypical chest pain, or dyspepsia. Alternatively, patients may present with symptoms such as occult blood in the stool or iron deficiency anemia. Patients may report mild or intermittent dysphagia, odynophagia, or a foreign body sensation. These symptoms generally warrant the diagnostic evaluation, including an esophagogastroduodenoscopy (EGD) (upper endoscopy), including a diagnostic mucosal biopsy. Some early cancers are diagnosed during routine upper endoscopic surveillance for Barrett’s esophagus. The symptoms of esophageal cancer generally progress rapidly.

 

The overall incidence of esophageal cancer ranges between 4.7 to 5.8 per 100,000 people per year. The 5-year survival rate for all patients diagnosed with Squamous cell esophageal cancer ranges from 15% to 20%. Males had a higher incidence of EC than females.

 

 

Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) competitive landscape includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake, and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Toripalimab       Shanghai Junshi Biosciences Co., Ltd    Phase 3

2          RO7121661 / RO7247669          Hoffmann-La Roche      Phase 2

3          CS1001            CStone Pharmaceuticals            Phase 3

4          Sintilimab          Innovent Biologics (Suzhou) Co. Ltd.      Phase 3

5          HLX10  Shanghai Henlius Biotech          Phase 3

6          Cisplatin            BeiGene           Phase 3

7          S095033           Servier  Phase 2

8          Lerotinib           Sunshine Lake Pharma Co., Ltd.            Phase 3

9          KN046  Jiangsu Alphamab Biopharmaceuticals Co., Ltd  Phase 2

10        GB1275            Gossamer Bio Inc.         Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more